$37.77
0.56% today
Nasdaq, Oct 31, 09:13 pm CET
ISIN
US4158581094
Symbol
HROW

Harrow Health, Inc. Stock price

$37.56
-10.62 22.04% 1M
+12.79 51.64% 6M
+4.01 11.95% YTD
-6.86 15.44% 1Y
+25.53 212.22% 3Y
+32.80 689.08% 5Y
+29.77 382.16% 10Y
+28.91 334.29% 20Y
Nasdaq, Closing price Thu, Oct 30 2025
+0.79 2.13%
ISIN
US4158581094
Symbol
HROW
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.6b
Net debt
$169.1m
Cash
$53.0m
Shares outstanding
36.7m
Valuation (TTM | estimate)
P/E
negative | 96.6
P/S
6.1 | 4.8
EV/Sales
6.9 | 5.4
EV/FCF
negative
P/B
28.0
Financial Health
Equity Ratio
17.9%
Return on Equity
-25.1%
ROCE
15.0%
ROIC
-
Debt/Equity
4.5
Financials (TTM | estimate)
Revenue
$227.7m | $287.3m
EBITDA
$32.4m | $73.6m
EBIT
$14.4m | $42.1m
Net Income
$-10.2m | $14.3m
Free Cash Flow
$-34.5m
Growth (TTM | estimate)
Revenue
47.7% | 43.9%
EBITDA
689.5% | 211.8%
EBIT
276.6% | 363.9%
Net Income
69.5% | 181.7%
Free Cash Flow
-67.0%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
14.2% | 25.6%
EBIT
6.3%
Net
-4.5% | 5.0%
Free Cash Flow
-15.1%
More
EPS
$-0.3
FCF per Share
$-0.9
Short interest
19.4%
Employees
382
Rev per Employee
$520.0k
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Harrow Health, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
228 228
48% 48%
100%
- Direct Costs 58 58
30% 30%
25%
170 170
55% 55%
75%
- Selling and Administrative Expenses 142 142
32% 32%
62%
- Research and Development Expense 13 13
30% 30%
6%
32 32
690% 690%
14%
- Depreciation and Amortization 18 18
47% 47%
8%
EBIT (Operating Income) EBIT 14 14
277% 277%
6%
Net Profit -10 -10
70% 70%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025
Positive
Seeking Alpha
16 days ago
Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth through 2034, with relatively conservative assumptions on margins and product adoption. I reiterate a "Buy" rating for HROW stock, with ~88% upside to a $72.7 base case fair value, including some risk ...
Neutral
GlobeNewsWire
25 days ago
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx.
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today